Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;4(2):149-55.
doi: 10.3978/j.issn.2218-6751.2014.12.02.

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim  1 , Jin-Haeng Chung  1
Affiliations
Review

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim et al. Transl Lung Cancer Res. 2015 Apr.

Abstract

Patients with non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements can derive significant clinical benefit from ALK tyrosine kinase inhibitor. Accurate patient identification is absolutely crucial for successful using ALK inhibitor treatment. However, lung cancer patients with ALK gene rearrangement after ALK inhibitor therapy eventually develop acquired resistance to treatment. In this review, the authors summarize the clinicopathologic features of ALK-rearranged NSCLC and the pros and cons of current diagnostic testing. In addition, we discuss the current diagnostic flow of ALK testing and consideration of rebiopsy sample during disease progression in patients treated by ALK inhibitors.

Keywords: Anaplastic lymphoma kinase (ALK) gene rearrangement; fluorescent in situ hybridization (FISH); histology; immunohistochemistry (IHC); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationship of ALK-rearranged tumors with the bronchiole. (A) Tumor cells invaded the adjacent bronchiolar epithelium (magnification, 10×); (B) at higher magnification, dysplastic epithelial lesions that resembled adjacent tumor cells continued the non-neoplastic bronchial epithelium (magnification, 20×). ALK, anaplastic lymphoma kinase.
Figure 2
Figure 2
(A) Dual nuclear expression of TTF-1 (magnification, 40×) and (B) p63 in ALK-rearranged tumors (magnification, 40×). ALK, anaplastic lymphoma kinase.
Figure 3
Figure 3
(A) ALK protein expression on immunohistochemistry using 5A4 antibody (magnification, 40×) and (B) D5F3 antibody (magnification, 40×). ALK, anaplastic lymphoma kinase.
See this image and copyright information in PMC

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. - PubMed
    1. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12. - PMC - PubMed
    1. Bang YJ. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med 2012;136:1201-4. - PubMed
    1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7. - PubMed
    1. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83. - PMC - PubMed